Rho Kinase Inhibitor and Alpha-1 Blocker Combination for Glaucoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma and ocular hypertension, particularly normal tension glaucoma, have limitations in potency and duration of ocular hypotensive effect, necessitating a more effective combination therapy.
Innovation Solution
Combining a Rho kinase inhibitor with an α1 blocker to enhance ocular hypotensive effects and prolong action, using specific compounds like (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine and bunazosin, administered together to promote aqueous outflow and lower intraocular pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing single drugs or conventional combinations are used for glaucoma treatment, then the treatment can be administered with standard therapies, but the ocular hypotensive effect is insufficient especially for normal tension glaucoma
Solution Approach 1:
The patent combines a Rho kinase inhibitor and an α1 blocker into a single ophthalmic composition that can be administered together. This merging of two different mechanisms of action (Rho kinase inhibition for trabecular outflow enhancement and α1 blockade for uveoscleral outflow promotion) creates a synergistic effect that achieves potent ocular hypotension in normal tension glaucoma and other glaucoma types where single agents are insufficient.
Solution Approach 2:
The invention creates a composite therapeutic agent by formulating both the Rho kinase inhibitor and α1 blocker in the same ophthalmic preparation. This composite approach allows simultaneous delivery of multiple active ingredients with complementary mechanisms, providing enhanced and sustained intraocular pressure reduction that adapts to various glaucoma pathologies including normal tension glaucoma.
2Duration of action of moving object
If existing treatments are used, then the administration process is simple, but the duration of ocular hypotensive action is short
Solution Approach 1:
By combining the Rho kinase inhibitor and α1 blocker into a single administered composition, the patent achieves prolonged ocular hypotensive duration through synergistic action while maintaining simple administration. The two agents work together to sustain intraocular pressure reduction longer than either agent alone, eliminating the need for complex multi-dose regimens or multiple separate administrations.
3Reliability
If combination therapy with multiple drugs is used, then the ocular hypotensive potency is enhanced, but the treatment complexity increases
Solution Approach 1:
The patent merges multiple therapeutic agents (Rho kinase inhibitor and α1 blocker) into a single ophthalmic composition that can be administered as one unified treatment. This approach maintains the enhanced ocular hypotensive potency of combination therapy while simplifying administration to a single step, thereby improving ease of operation and patient compliance without sacrificing therapeutic effectiveness.
Data Source
Figure 1~2
AI summary
There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. A preventive or a remedy for glaucoma comprising a Rho kinase inhibitor and an α1 blocker in combination.